A pharmaceutical composition for treatment of a person afflicted or in risk of becoming afflicted of impaired glucose tolerance (IGT) and/or type-2 diabetes comprising an effective amount of relaxin polypeptides for protecting beta-cells and beta-cell function against the effects of high blood glucose (glucotoxicity). Methods of treatment of persons afflicted of dysglycaemias and for protection of beta cells of the islets of Langerhans and beta-cell function in patients having type-2 diabetes.
